Keith Regnante
2020
In 2020, Keith Regnante earned a total compensation of $2.4M as Chief Financial Officer at Keros Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $138,000 |
|---|---|
| Option Awards | $1,901,352 |
| Salary | $323,170 |
| Other | $521 |
| Total | $2,363,042 |
Regnante received $1.9M in option awards, accounting for 80% of the total pay in 2020.
Regnante also received $138K in non-equity incentive plan, $323.2K in salary and $521 in other compensation.
Rankings
In 2020, Keith Regnante's compensation ranked 4,800th out of 13,090 executives tracked by ExecPay. In other words, Regnante earned more than 63.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,800 out of 13,090 | 63rd |
Division Manufacturing | 1,954 out of 5,618 | 65th |
Major group Chemicals And Allied Products | 769 out of 2,251 | 66th |
Industry group Drugs | 662 out of 1,951 | 66th |
Industry Pharmaceutical Preparations | 501 out of 1,456 | 66th |
Source: SEC filing on April 19, 2021.
Regnante's colleagues
We found two more compensation records of executives who worked with Keith Regnante at Keros Therapeutics in 2020.